Surgical cytoreduction in stage IV endometrioid endometrial carcinoma Journal Article
| Authors: | Shih, K. K.; Yun, E.; Gardner, G. J.; Barakat, R. R.; Chi, D. S.; Leitao, M. M. Jr |
| Article Title: | Surgical cytoreduction in stage IV endometrioid endometrial carcinoma |
| Abstract: | Objective: To evaluate the role of surgical cytoreduction and the amount of residual disease in patients with newly diagnosed stage IV endometrioid endometrial carcinoma (EC). Methods: Patients with stage IV EC of endometrioid histology who underwent surgery at our institution from 1977 to 2003 were identified. Patients with microscopic stage IV disease were excluded. Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan Meier method and compared with log-rank test. Results: A total of 58 patients were identified, of which 9 (15.5%) had no gross residual (NGR) after surgery, 11 (19.0%) had residual disease ≤ 1 cm, 32 (55.1%) had residual disease > 1 cm, and 6 (10.3%) had no cytoreduction attempted. The median PFS was 11.1 months (95% CI, 9.8-12.3) and the median OS was 19.2 months (95% CI, 8.5-29.9) for the cohort. The median PFS was 40.3 months (95% CI, 0-93.9) for patients with NGR disease, 11 months (95% CI, 9.9-12.1) for patients with any residual disease, and 2.2 months (95% CI, 0.1-4.2) for patients who did not have attempted cytoreduction (P < 0.001). The median OS was 42.2 months (95% CI, not estimable) for patients with NGR disease, 19 months (95% CI, 13.9-24.1) for patients with any residual disease, and 2.2 months (95% CI, 0.1-4.2) for patients that did not have attempted cytoreduction (P < 0.001). Conclusion: Though stage IV endometrioid EC has a poor prognosis, surgical cytoreduction to no gross residual disease in a highly select group of patients is associated with improved survival. © 2011 Elsevier Inc. |
| Keywords: | adult; controlled study; aged; major clinical study; overall survival; doxorubicin; fluorouracil; paclitaxel; adjuvant therapy; cancer adjuvant therapy; cancer radiotherapy; cancer staging; endometrioid carcinoma; endometrium carcinoma; surgical cytoreduction; cytoreductive surgery; carboplatin; progression free survival; cyclophosphamide; cancer hormone therapy; minimal residual disease; tamoxifen; kaplan meier method; navelbine; endometrium; log rank test; megestrol; medroxyprogesterone; endometrioid endometrial carcinoma; stage iv endometrial cancer |
| Journal Title: | Gynecologic Oncology |
| Volume: | 122 |
| Issue: | 3 |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2011-09-01 |
| Start Page: | 608 |
| End Page: | 611 |
| Language: | English |
| DOI: | 10.1016/j.ygyno.2011.05.020 |
| PROVIDER: | scopus |
| PUBMED: | 21664663 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 3 October 2011" - "CODEN: GYNOA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work